secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001193125-23-267243
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.01, 9.01, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06
LLM model:  deepseek-v4-flash:cloud@v2

enGene closes business combination with SPAC Forbion European Acquisition Corp., becomes public on Nasdaq
--------------------------------------------------------------------------------

- New enGene shares and warrants trade on Nasdaq under 'ENGN' and 'ENGNW' starting Nov 1, 2023.
- Approximately 10.4 million FEAC Class A shares were redeemed in connection with the deal.
- Post-combination, Forbion Growth (31.9%), Lumira Ventures (14.4%), and others are top shareholders.
- Company retains enGene's focus on non-viral gene therapies for mucosal tissues, lead candidate EG-70 for NMIBC.
- PIPE financing was consummated alongside the transaction (amount not disclosed in this filing).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/0001193125-23-267243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-267243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer